CT:VQ™ gives physicians access to ventilation and perfusion imaging and data derived directly from routine, non-contrast, chest CT scans. CT:VQ™ delivers regional functional lung information without the use of injected contrast agents, radiotracers, or dedicated nuclear medicine infrastructure.

“TGA approval marks an important milestone for respiratory diagnostics in our home market,” said Andreas Fouras, Founder, Managing Director and CEO of 4DMedical.